7 completed, 1 terminated. 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 7, Terminated 1 |
Follow tabalumab: new trials by email Literature Review of tabalumab trials Research Report on tabalumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM) Placebo, Dexamethasone, Bortezomib - Multiple Myeloma | Phase 2 | Completed | Eli Lilly and Company | 220 | 2012-07-01 | 2019-10-08 |
| A Study of LY2127399 in Rheumatoid Arthritis LY2127399 - Rheumatoid Arthritis | Phase 2 | Terminated | Eli Lilly and Company | 2 | 2012-05-01 | 2018-04-26 |
| A Study in Participants With End-Stage Renal Disease LY2127399 - Kidney Failure, Chronic | Phase 2 | Completed | Eli Lilly and Company | 18 | 2011-04-01 | 2018-05-14 |
| A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) LY2127399, Placebo - Relapsing-Remitting Multiple Sclerosis | Phase 2 | Completed | Eli Lilly and Company | 245 | 2009-04-01 | 2018-11-15 |
| An Open Label Extension Study in Participants With Rheumatoid Arthritis LY2127399 - Rheumatoid Arthritis | Phase 2 | Completed | Eli Lilly and Company | 182 | 2009-02-01 | 2018-04-25 |
| A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy LY2127399, Placebo - Rheumatoid Arthritis | Phase 2 | Completed | Eli Lilly and Company | 158 | 2008-10-01 | 2018-07-10 |
| A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy LY2127399, Placebo - Arthritis, Rheumatoid | Phase 2 | Completed | Eli Lilly and Company | 100 | 2008-06-01 | 2018-12-06 |
| A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Participants With Rheumatoid Arthritis LY2127399, Placebo - Arthritis, Rheumatoid | Phase 2 | Completed | Eli Lilly and Company | 136 | 2006-03-28 | 2019-09-10 |
Arthritis, Rheumatoid (5) · Arthritis (2) · Kidney Failure, Chronic (1) · Multiple Myeloma (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Recurrence (1) · Sclerosis (1) · Uremia (1)
United States (7) · Germany (5) · Poland (5) · Mexico (4) · Romania (4) · Brazil (3) · Canada (3) · Hungary (3) · Argentina (2) · Australia (2) · Austria (2) · Belgium (2) · Chile (2) · France (2) · India (2)
PMID 23268367, PMID 23359344, PMID 23599435, PMID 25168268, PMID 26780484